Babrowski, Trissa MD*; Holbrook, Christopher MD*; Moss, Jonathan MD†; Gottlieb, Lawrence MD‡; Valuckaite, Vesta MD*; Zaborin, Alexander PhD*; Poroyko, Valeriy PhD*; Liu, Donald C. MD, PhD*; Zaborina, Olga PhD*; Alverdy, John C. MD, FACS*
*Center of Surgical Infection Research and Therapeutics, Department of Surgery, Pritzker School of Medicine;
†Department of Anesthesia and Critical Care;
‡Burn and Complex Wound Center, University of Chicago, Chicago, IL.
Reprints: John C. Alverdy, MD, FACS, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland MC 6090, Chicago, IL 60637. E-mail: [email protected].
O.Z. and J.C.A. are senior co-authors.
Disclosure: Supported by NIH RO1 GM062344-11 and by the University of Chicago, BSD Imagine Research Institute for pilot research projects using animal imaging. Dr Jonathan Moss serves as a paid consultant to Progenics Pharmaceuticals, Inc., has a financial interest in MNTX as a patent holder through the University of Chicago, and receives stock options from Progenics.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.annalsofsurgery.com).